Palforzia

Aimmune Therapeutics Inc (NASDAQ: AIMT) shares, which recovered Monday following an earnings-induced sell-off Friday, are adding to the gains.  The Aimmune Catalyst: Shares of Brisbane, California-based Aimmune — which has a commercial product in Palforzia, used to treat peanut allergy...

Aimmune Therapeutics Inc (NASDAQ: AIMT) recently received FDA approval for its peanut allergy drug Palforzia.  The Aimmune Analyst Baird analyst Brian Skorney maintained an Outperform rating on Aimmune with a $64 price target. The Aimmune Thesis With NESTLE S A/S ADR (OTC: NSRGY)...

Aimmune Therapeutics Inc (NASDAQ: AIMT) announced late Friday that it received FDA approval for Palforzia, its oral immunotherapy to treat peanut allergy. The Aimmune Analysts Baird analyst Brian Skorney maintained an Outperform rating and $64 price target for Aimmune shares. RBC Capital...

Shares of biopharma Aimmune Therapeutics Inc (NASDAQ: AIMT) advanced strongly in after-hours trading Friday following a positive FDA verdict for Aimunne's peanut allergy drug. 9-Year Wait Ends The FDA approved Palforzia allergen powder for treating patients with confirmed diagnosis of...

A novel oral immunotherapy developed by Aimmune Therapeutics Inc (NASDAQ: AIMT) to treat peanut allergy is on the cusp of FDA approval after a nearly nine-year-long journey from lab to shelf. Benzinga spoke to Aimmune Chief Financial Officer Eric Bjerkholt in a freewheeling chat. It'...